History and evolution of influenza control through vaccination: From the first monovalent vaccine to universal vaccines

Journal of Preventive Medicine and Hygiene

Volumn 57, Issue 3, 2016, Pages E115-E120

  Barberis, I ^a   Myles, P ^b   Ault, S K ^c   Bragazzi, N L ^a   Martini, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

History of medicine; Influenza; Vaccination

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; SUBUNIT VACCINE;

DISEASE SURVEILLANCE; DRUG FORMULATION; DRUG MEGADOSE; EPIDEMIC; GENETIC REASSORTMENT; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA VACCINATION; NONHUMAN; PANDEMIC INFLUENZA; REVIEW; VIRUS ISOLATION; ORTHOMYXOVIRIDAE; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VACCINATION;

EID: 84994008683     PISSN: 11212233     EISSN: 24214248     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs. J Prev Med Hyg 2014;55:69-85.
2. Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg 2014;55:109-29.
3. Hause BM, Collin EA, Liu R, Huanq B, Shenq Z, Lu W, Wanq D, Nelson EA, Li F. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. MBio 2014;5:e00031-14.
4. Collin EA, Sheng Z, Lang Y, Ma W, Hause BM, Li F. Cocirculation of two distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J Virol 2015;89:1036-42.
5. Ducatez MF, Pelletier C, Meyer G. Influenza D virus in cattle, France, 2011-2014. Emerg Infect Dis 2015;21:368-71.
6. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm 2015;94:251-63.
7. Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis 2008;12:347-50.
8. Kohn GC Encyclopedia of Plague and Pestilence: From Ancient Times to the Present. Infobase Publishing 2007.
9. Beveridge WIB. Influenza: The Last Great Plague. London: Heineman Educational Books 1977.
10. Wood JM, Influenza. In: Crovari P, Principi N, eds. Le vaccinazioni. Pisa: Pacini Editore 2000.
11. Kuszewski K, Brydak. L. The epidemiology and history of influenza. Biomed Pharmacoter 2000;54:188-95.
12. Gintrac H. Grippe. In: Nouveau dictionnaire de médicine et de chirurgie pratiques, directeur de la redaction: le docteur Jaccoud. 1872, Tome 16, page. 728-753.
13. de Souza CM. The Spanish flu epidemic: a challenge to Bahian medicine. Hist Cienc Saude Manguinhos 2008;15:945-72.
14. Potter CW. A history of influenza. J Appl Microbiol 2001;91:572-9.
15. Waring J.I. A History of Medicine in South Carolina 1900-70. South Carolina Medical Association 1971.
16. Bazin H. Vaccination: a history. France: Editions John Libbey Eurotext Montrouge 2011.
17. Renaud F, Hansen W, Freney J. Dictionnaire des precurseurs en bacteriologie, SFM éditions Eska, 2005, 249 pages.
18. Craddock S, Giles-Vernick T, Gunn JL. Influenza and Public Health: Learning from Past Pandemics. Earthscan, 2010 - 293 pages.
19. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933;2:66-8.
20. Smith W, Andrewes CH, Stuart Harris CH. The immunization of human volunteers. Special Rep Ser Med Res Council 1938;228:137-44.
21. Francis T Jr. Vaccination against influenza. Bull World Health Organ 1953;8:725-41.
22. Burnett FM. Influenza virus infection of the chick embryo lung. Br J Exp Pathol 1940;21:147-53.
23. Stanley WM. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J Exp Med 1945;81:193-218.
24. Davenport FM. The search for the ideal influenza vaccine. Postgraduate Medical Journal 1979;55:78-86.
25. Francis T. Vaccination against influenza. Bull World Health Org 1953;8:725-41.
26. Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011;28:93-106.
27. Barberis I, Martini M, Iavarone F, Orsi A. Available influenza vaccines: immunization strategies, history and new tools for fighting the disease. J Prev Med Hyg 2016;57:E41-6.
28. Francis T jr, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced influenza A. J Clin Invest 1945;24:536-46.
29. Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza and Other Respiratory Viruses 2016;10:354-60.
30. Keitel WA, Neuzil KM, Treanor J. Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines. Textbook of Influenza. Wiley-Blackwell 2013, pp. 311-326.
31. WHO Global Influenza Surveillance Network (GISN) http://www. who.int/influenza/gisrs-laboratory/en/[Accessed 20/9/2016].
32. Oxford J, Gilbert A, Lambkin-Williams R. Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic. In: Rappuoli R, Del Giudice G, eds. Influenza vaccines for the future. Springer Verlag, 2011.
33. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015;14:167-82.
34. Zaman M, Ashraf S, Dreyer NA, Toovey S. Human infection with avian influenza virus, Pakistan, 2007. Emerg Infect Dis 2011;17:1056-9.
35. Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines for adults. J Infect Dis 1977;136:722-30
36. Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore 2008;37:510-7.
37. Crovari P, Alberti M, Alicino C. History and evolution of influenza vaccines. J Prev Med Hyg 2011;52:91-4.
38. Gianchecchi E, Trombetta C, Piccirella S, Montomoli E. Evaluating influenza vaccines: progress and perspectives. Future Virology 2016;11:379-93.
39. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live attenuated influenza vaccines in the U.S.A. and U.S.S.R. Antiviral Res 1982;1:339-65.
40. Food and Drug Administration (FDA). FluMist. Prior Approval Supplemental BLA. April 2007. Available at: http://www.fda. gov/ohrms/dockets/ac/07/briefing/2007-4292B1-02.pdf.[Accessed 20/9/2016].
41. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Mølbak K, R Pebody, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, S Vong, Bresee J, Widdowson MA. Estimated global mortality associated with the ?rst 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12:687-95.
42. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc 2010;85: 64-76.
43. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172-80.
44. Durando P, Iudici R, Alicino C, Alberti M, de Florentiis, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011;7(Suppl):29-40.
45. Holland D, Booy R, De Looze F, Eizenberg P, Mc Donald J, Karrasch J, Mc Keirnan M, Salem H, Mills G, Reid J, Weber F, Saville M. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650-8.
46. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-12.
47. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94.
48. Bragazzi NL, Orsi A, Ansaldi F, Gasparini R, Icardi G. Fluzone ® Intra-dermal (Intanza®/Istivac® Intra-dermal): an updated overview. Hum Vaccin Immunother 2016, in press.
49. Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, Ansaldi F. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg 2016;57:E28-33.
50. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against in?uenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011;29:7733-9.
51. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox M. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011;29:2272-8.
52. Sridhar S. Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines. Front Immunol 2016;7:195.
53. Wiersma LC, Rimmelzwaan GF, de Vries RD. Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines (Basel) 2015;3:239-62.